You're supporting incredible advances in melanoma research.
Professor Brian Gabrielli and his Mater Melanoma Research team are expanding treatment options to improve life expectancy for melanoma patients.
With your support, Mater is making incredible advances in melanoma research. Professor Gabrielli and his team’s goal to develop effective treatments for those who do not respond to current standard of care is making significant inroads.
Thanks to ongoing commitment, we are now able to start negotiations to fund an early phase clinical trial for late-stage melanoma patients who have exhausted their standard of care.
Fundraising efforts are being invested in the health of our community to help us find better diagnostics, treatments and life-saving outcomes for melanoma patients.
This support enables outstanding research and great strides in the search for life-changing treatments to provide better quality of life and the greatest gift of all for melanoma patients and their families – time.
Professor Gabrielli and his co-researchers have had an exciting 12 months. Their recent work has seen the team investigate the immune effects of a novel therapy and shown that it not only selectively kills a broad range of advanced melanomas, but that in killing the melanoma it is also triggering an anti-tumour immune response.
The current research explores how we can improve and extend the immune response using immunotherapies and has led to the recent collaboration with an international pharmaceutical company to explore an experimental drug combination of the two treatments.
“We are at the front of the wave that is likely to change how we understand and treat disease,” Professor Gabrielli says. “Being a part of this exciting progress, contributing to new ideas, discoveries and hopefully treatments, makes the hard slog of everyday research worthwhile. Thank you for supporting our research and helping us harness the body’s immune system to recognise and fight cancer.”
Research from Profesor Gabrielli’s team has demonstrated that the combination of novel targeted therapy and immunotherapy is effective against a high proportion of melanomas, including close to half of patients with advanced disease who do not respond well, or at all, to the current, clinically-used immune checkpoint inhibitors.
This is a major step forward in melanoma research and these advances are only possible thanks to fundraising support which translates into precious time for those who may have not had that option even 12 months ago.
As melanoma patient and research advocate, Gina Savage, states: “I had the privilege of being taken through Professor Gabrielli’s labs at Mater Research and I hope that his research will get to a point where cancer doesn’t cause as much heartbreak as it does today; and where people will be able to live with their disease, as opposed to dying.”
We are at the front of the wave that is likely to change how we understand and treat disease. Professor Gabrielli says. Being a part of this exciting progress, contributing to new ideas, discoveries and hopefully treatments, makes the hard slog of everyday research worthwhile. Thank you for supporting our research and helping us harness the body’s immune system to recognise and fight cancer.